

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

**DELAY IN DESPATCH OF CIRCULAR
AND
APPLICATION FOR WAIVER FROM STRICT COMPLIANCE
WITH RULE 14.41(A) OF THE LISTING RULES**

Reference is made to the joint announcement jointly published by Aceso Life Science Group Limited (the “**Company**”) and HTICI on 13 June 2023 in relation to the major transaction of the Company relating to Bonds Purchase (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

As the Bonds Purchase was approved by way of written shareholders’ approval, pursuant to Rule 14.41(a) of the Listing Rules, a circular of the Company (the “**Circular**”) containing, among other information, further details of the Bonds Purchase and other information as required under the Listing Rules must be despatched within 15 business days after publication of the Announcement, which is on or before 5 July 2023.

As additional time is required to prepare and finalise, among other things, the relevant information, including but not limited to the indebtedness statement of the Company, for inclusion in the Circular, the Company has applied to the Stock Exchange for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules for an extension of the date of despatch of the Circular to the Shareholders to a date on or before 4 August 2023 (the “**Waiver**”). Further announcement will be made by the Company upon the Stock Exchange granting the Waiver to the Company.

By order of the Board
Aceso Life Science Group Limited
Fok Chi Tak
Executive Director

Hong Kong, 5 July 2023

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Xu Haiying, Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; and three independent non-executive Directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.